India looks to cut reliance on China for APIs
NEW DELHI – In a bid to limit what is seen as excessive dependence on active pharmaceutical ingredients (APIs) from China, the Indian government has announced a $394 million scheme to promote the development of three bulk drug parks.The government would use the funds to finance infrastructure construction over the next five years at the three industrial parks focused on the manufacturing of APIs and bulk drugs.
